This clinical trial is focused on studying the effects of colon cancer treatment. Specifically, it examines the use of acetylsalicylic acid, commonly known as aspirin, in patients who have had surgery to remove colon cancer. The trial aims to understand how taking 80 mg of aspirin daily for five years might affect the chances of cancer returning and overall survival in patients with stage II and III colon cancer. Stage II and III refer to the extent of cancer spread, with stage III being more advanced than stage II.

Participants in the study will be randomly assigned to receive either aspirin or a placebo, which is a tablet that looks like aspirin but does not contain any active medication. This is done to compare the effects of aspirin against no active treatment. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving aspirin and who is receiving the placebo, to ensure unbiased results.

The main goal of the study is to see if aspirin can improve the five-year overall survival rate, which is the percentage of people who are still alive five years after treatment. Additionally, the study will look at other outcomes such as disease-free survival, which measures the time patients remain free from cancer, and time to treatment failure, which tracks how long the treatment remains effective. The trial is expected to continue until the end of 2027.